본문 바로가기
KERD
논문KCI 등재

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Rohit Loomba|Theresa J. Hydes|Sujan Ravi|Meagan E. Gray
대한간학회 (The korean Association for the Study of the Liver)|2020.10|Clinical and Molecular Hepatology|제26권 제4호|pp. 383-400|DOI 10.3350/cmh.2020.0067

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

DietVegetarianHealthyNonalcoholic fatty liver disease

초록

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet is recommended at this time. In this narrative review we examine the pathophysiology behind specific macronutrient components that can either promote or reverse NAFLD to help inform more specific dietary recommendations. Overall, the data supports reducing saturated fat, refined carbohydrates, and red and processed meats in the diet, and increasing the consumption of plant-based foods. Diets that incorporate these recommendations include plant-based diets such as the Dietary Approaches to Stop Hypertension, Mediterranean, vegetarian, and vegan diets.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet is recommended at this time. In this narrative review we examine the pathophysiology behind specific macronutrient components that can either promote or reverse NAFLD to help inform more specific dietary recommendations. Overall, the data supports reducing saturated fat, refined carbohydrates, and red and processed meats in the diet, and increasing the consumption of plant-based foods. Diets that incorporate these recommendations include plant-based diets such as the Dietary Approaches to Stop Hypertension, Mediterranean, vegetarian, and vegan diets.

참고문헌 (156)

  1. Sayiner M, "Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world", Clin Liver Dis, 20, pp.205~214 (2016)
  2. Vernon G, "Systematic review : the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults", Aliment Pharmacol Ther, 34, pp.274~285 (2011)
  3. Leite NC, "Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus", Liver Int, 29, pp.113~119 (2009)
  4. Prashanth M, "Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus", J Assoc Physicians India, 57, pp.205~210 (2009)
  5. Boza C, "Predictors of nonalcoholic steatohepatitis(NASH)in obese patients undergoing gastric bypass", Obes Surg, 15, pp.1148~1153 (2005)
  6. Haentjens P, "Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics", Acta Clin Belg, 64, pp.483~493 (2009)
  7. Machado M, "Hepatic histology in obese patients undergoing bariatric surgery", J Hepatol, 45, pp.600~606 (2006)
  8. Colicchio P, "Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in south Italy", Ann Nutr Metab, 49, pp.289~295 (2005)
  9. Beymer C, "Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery", Arch Surg, 138, pp.1240~1244 (2003)
  10. Donnelly KL, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease", J Clin Invest, 115, pp.1343~1351 (2005)
  11. Sanyal AJ, "Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
  12. Lambert JE, "Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease", Gastroenterology, 146, pp.726~735 (2014)
  13. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the study of liver diseases", Hepatology, 67, pp.328~357 (2018)
  14. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
  15. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378.e5 (2015)
  16. Wehmeyer MH, "Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern", Medicine(Baltimore), 95, pp.e3887~ (2016)
  17. Huang MA, "One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis : a pilot study", Am J Gastroenterol, 100, pp.1072~1081 (2005)
  18. Parker R, "The role of adipose tissue in fatty liver diseases", Liver Res, 2, pp.35~42 (2018)
  19. Abenavoli L, "Role of adipokines and cytokines in nonalcoholic fatty liver disease", Rev Recent Clin Trials, 9, pp.134~140 (2014)
  20. Tilg H, "NAFLD and diabetes mellitus", Nat Rev Gastroenterol Hepatol, 14, pp.32~42 (2017)
  21. Lazo M, "Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes", Diabetes Care, 33, pp.2156~2163 (2010)
  22. Promrat K, "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis", Hepatology, 51, pp.121~129 (2010)
  23. Ueno T, "Therapeutic effects of restricted diet and exercise in obese patients with fatty liver", J Hepatol, 27, pp.103~107 (1997)
  24. Kirk E, "Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction", Gastroenterology, 136, pp.1552~1560 (2009)
  25. Musso G, "Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease(NAFLD) : a systematic review and meta-analysis of randomised trials", Diabetologia, 55, pp.885~904 (2012)
  26. Jensen MD, "2013 AHA", ACC, American Heart Association task force on practice guidelines and the obesity society, pp.Circulation, 2014[DOI]
  27. Rynders CA, "Effectiveness of intermittent fasting and time-restricted feeding compared to continuous energy restriction for weight loss", Nutrients, 11, pp.2442~ (2019)
  28. Johari MI, "A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease", Sci Rep, 9, pp.11232~ (2019)
  29. Cai H, "Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease : a randomised controlled trial", BMC Gastroenterol, 19, pp.219~ (2019)
  30. Cross AJ, "A prospective study of red and processed meat intake in relation to cancer risk", PLoS Med, 4, pp.e325~ (2007)
  31. Pan A, "Red meat consumption and mortality : results from 2 prospective cohort studies", Arch Intern Med, 172, pp.555~563 (2012)
  32. Sinha R, "Meat intake and mortality : a prospective study of over half a million people", Arch Intern Med, 169, pp.562~571 (2009)
  33. Rohrmann S, "Meat consumption and mortalityresults from the European prospective investigation into cancer and nutrition", BMC Med, 11, pp.63~ (2013)
  34. Etemadi A, "Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP diet and health study : population based cohort study", BMJ, 357, pp.j1957~ (2017)
  35. Bellavia A, "High red meat intake and all-cause cardiovascular and cancer mortality : is the risk modified by fruit and vegetable intake?", Am J Clin Nutr, 104, pp.1137~1143 (2016)
  36. van den Brandt PA, "Red meat, processed meat, and other dietary protein sources and risk of overall and cause-specific mortality in the Netherlands cohort study", Eur J Epidemiol, 34, pp.351~369 (2019)
  37. Abete I, "Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality : a meta-analysis of cohort studies", Br J Nutr, 112, pp.762~775 (2014)
  38. Larsson SC, "Red meat and processed meat consumption and all-cause mortality : a meta-analysis", Am J Epidemiol, 179, pp.282~289 (2014)
  39. Wang X, "Red and processed meat consumption and mortality : dose-response meta-analysis of prospective cohort studies", Public Health Nutr, 19, pp.893~905 (2016)
  40. Takata Y, "Red meat and poultry intakes and risk of total and cause-specific mortality : results from cohort studies of Chinese adults in Shanghai", PLoS One, 8, pp.e56963~ (2013)
  41. Song M, "Association of animal and plant protein intake with all-cause and cause-specific mortality", JAMA Intern Med, 176, pp.1453~1463 (2016)
  42. Alferink LJ, "Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population : the Rotterdam Study", Gut, 68, pp.1088~1098 (2019)
  43. Rietman A, "Associations between dietary factors and markers of NAFLD in a general Dutch adult population", Eur J Clin Nutr, 72, pp.117~123 (2018)
  44. Zelber-Sagi S, "Long term nutritional intake and the risk for nonalcoholic fatty liver disease(NAFLD) : a population based study", J Hepatol, 47, pp.711~717 (2007)
  45. Zelber-Sagi S, "High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance", J Hepatol, 68, pp.1239~1246 (2018)
  46. Wolk A, "Potential health hazards of eating red meat", J Intern Med, 281, pp.106~122 (2017)
  47. Menon S, "Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome", Cell, 156, pp.771~785 (2014)
  48. Kim JB, "Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1", SREBP1, 1998, pp.101, 1~9
  49. Li S, "Bifurcation of insulin signaling pathway in rat liver : mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis", Proc Natl Acad Sci U S A, 107, pp.3441~3446 (2010)
  50. Laeger T, "FGF21 is an endocrine signal of protein restriction", J Clin Invest, 124, pp.3913~3922 (2014)
  51. Gallinetti J, "Amino acid sensing in dietary-restriction-mediated longevity : roles of signal-transducing kinases GCN2 and TOR", Biochem J, 449, pp.1~10 (2013)
  52. Holland WL, "An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice", Cell Metab, 17, pp.790~797 (2013)
  53. Nishimura T, "Identification of a novel FGF, FGF-21, preferentially expressed in the liver", Biochim Biophys Acta, 1492, pp.203~206 (2000)
  54. Domouzoglou EM, "Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis", Am J Clin Nutr, 93, pp.901S~905S (2011)
  55. Xu J, "Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice", Diabetes, 58, pp.250~259 (2009)
  56. Aissa AF, "Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice", Mol Nutr Food Res, 58, pp.1502~1512 (2014)
  57. Weltman MD, "Increased hepatocyte CYP2E1expression in a rat nutritional model of hepatic steatosis with inflammation", Gastroenterology, 111, pp.1645~1653 (1996)
  58. Wang Z, "Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease", Nature, 472, pp.57~63 (2011)
  59. Koeth RA, "Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis", Nat Med, 19, pp.576~585 (2013)
  60. Tang WH, "Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk", N Engl J Med, 368, pp.1575~1584 (2013)
  61. Chen YM, "Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults", Sci Rep, 6, pp.19076~ (2016)
  62. Wu GD, "Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production", Gut, 65, pp.63~72 (2016)
  63. McCarty MF, "GCN2 and FGF21 are likely mediators of the protection from cancer, autoimmunity, obesity, and diabetes afforded by vegan diets", Med Hypotheses, 83, pp.365~371 (2014)
  64. Markova M, "Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes", Gastroenterology, 152, pp.571~585.e8 (2017)
  65. Noto H, "Low-carbohydrate diets and all-cause mortality : a systematic review and meta-analysis of observational studies", PLoS One, 8, pp.e55030~ (2013)
  66. Volynets V, "Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease(NAFLD)", Dig Dis Sci, 57, pp.1932~1941 (2012)
  67. Kwon OW, "Carbohydrate but not fat is associated with elevated aminotransferases", Aliment Pharmacol Ther, 35, pp.1064~1072 (2012)
  68. Cortez-Pinto H, "How different is the dietary pattern in non-alcoholic steatohepatitis patients?", Clin Nutr, 25, pp.816~823 (2006)
  69. Papandreou D, "Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease", Appetite, 59, pp.939~944 (2012)
  70. Ouyang X, "Fructose consumption as a risk factor for non-alcoholic fatty liver disease", J Hepatol, 48, pp.993~999 (2008)
  71. Thuy S, "Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake", J Nutr, 138, pp.1452~1455 (2008)
  72. Ma J, "Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts", J Hepatol, 63, pp.462~469 (2015)
  73. Assy N, "Soft drink consumption linked with fatty liver in the absence of traditional risk factors", Can J Gastroenterol, 22, pp.811~816 (2008)
  74. Toshimitsu K, "Dietary habits and nutrient intake in non-alcoholic steatohepatitis", Nutrition, 23, pp.46~52 (2007)
  75. Abdelmalek MF, "Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease", Hepatology, 51, pp.1961~1971 (2010)
  76. Ma L, "Direct role of ChREBP. Mlx in regulating hepatic glucose-responsive genes", J Biol Chem, 280, pp.12019~12027 (2005)
  77. Alwahsh SM, "Dietary fructose as a risk factor for nonalcoholic fatty liver disease(NAFLD)", Arch Toxicol, 91, pp.1545~1563 (2017)
  78. Stanhope KL, "Consuming fructose-sweetened, not glucosesweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight", obese humans, 2009, pp.119, 1322~1334
  79. Dirlewanger M, "Effects of fructose on hepatic glucose metabolism in humans", Am J Physiol Endocrinol Metab, 279, pp.E907~E911 (2000)
  80. Pollock NK, "Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents", J Nutr, 142, pp.251~257 (2012)
  81. Schwarz JM, "Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat", J Clin Endocrinol Metab, 100, pp.2434~2442 (2015)
  82. Crescenzo R, "Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose", Eur J Nutr, 52, pp.537~545 (2013)
  83. Renaud HJ, "Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis", PLoS One, 9, pp.e88584~ (2014)
  84. Ross AB, "Increasing whole grain intake as part of prevention and treatment of nonalcoholic fatty liver disease", Int J Endocrinol, 2013, pp.585876~ (2013)
  85. Haghighatdoost F, "The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease : a systematic review and meta-analysis of clinical trials", J Res Med Sci, 21, pp.53~ (2016)
  86. Browning JD, "Short-term weight loss and hepatic triglyceride reduction : evidence of a metabolic advantage with dietary carbohydrate restriction", Am J Clin Nutr, 93, pp.1048~1052 (2011)
  87. Tendler D, "The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease : a pilot study", Dig Dis Sci, 52, pp.589~593 (2007)
  88. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
  89. Chiu S, "Effect of fructose on markers of non-alcoholic fatty liver disease(NAFLD) : a systematic review and meta-analysis of controlled feeding trials", Eur J Clin Nutr, 68, pp.416~423 (2014)
  90. Chung M, "Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health : a systematic review and metaanalysis", Am J Clin Nutr, 100, pp.833~849 (2014)
  91. Schwimmer JB, "Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys : a randomized clinical trial", JAMA, 321, pp.256~265 (2019)
  92. Volynets V, "A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease(NAFLD) : a pilot study", Eur J Nutr, 52, pp.527~535 (2013)
  93. Maersk M, "Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot : a 6-mo randomized intervention study", Am J Clin Nutr, 95, pp.283~289 (2012)
  94. Sevastianova K, "Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans", Am J Clin Nutr, 96, pp.727~734 (2012)
  95. Reynolds A, "Carbohydrate quality and human health : a series of systematic reviews and meta-analyses", Lancet, 393, pp.434~445 (2019)
  96. Zong G, "Whole grain intake and mortality from all causes, cardiovascular disease, and cancer : a metaanalysis of prospective cohort studies", Circulation, 133, pp.2370~2380 (2016)
  97. Zolfaghari H, "Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals", Int J Prev Med, 7, pp.98~ (2016)
  98. Rocha R, "Non alcoholic fatty liver disease : treatment with soluble fibres", Arq Gastroenterol, 44, pp.350~352 (2007)
  99. Truswell AS, "Dietary fibre and plasma lipids", Eur J Clin Nutr, 49(Suppl 3), pp.S105~S109 (1995)
  100. Anderson JW, "Dietary fiber : hyperlipidemia, hypertension, and coronary heart disease", Am J Gastroenterol, 81, pp.907~919 (1986)
  101. Björck I, "The glycaemic index : importance of dietary fibre and other food properties", Proc Nutr Soc, 62, pp.201~206 (2003)
  102. Cantero I, "Fruit fiber consumption specifically improves liver health status in obese subjects under energy restriction", Nutrients, 9, pp.667~ (2017)
  103. Daubioul CA, "Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis : results of a pilot study", Eur J Clin Nutr, 59, pp.723~726 (2005)
  104. Musso G, "Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis", Hepatology, 37, pp.909~916 (2003)
  105. Della Pepa G, "Isocaloric dietary changes and non-alcoholic fatty liver disease in high cardiometabolic risk individuals", Nutrients, 9, pp.1065~ (2017)
  106. Nolan CJ, "Lipotoxicity : why do saturated fatty acids cause and monounsaturates protect against it?", J Gastroenterol Hepatol, 24, pp.703~706 (2009)
  107. Leamy AK, "Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease", Prog Lipid Res, 52, pp.165~174 (2013)
  108. Yokoi H, "Hydroxy monounsaturated fatty acids as agonists for peroxisome proliferator-activated receptors", Biol Pharm Bull, 33, pp.854~861 (2010)
  109. Khan SA, "Unraveling the complex relationship triad between lipids, obesity, and inflammation", Mediators Inflamm, 2014, pp.502749~ (2014)
  110. Stillwell W, "Docosahexaenoic acid : membrane properties of a unique fatty acid", Chem Phys Lipids, 126, pp.1~27 (2003)
  111. Caviglia JM, "Different fatty acids inhibit apoB100 secretion by different pathways : unique roles for ER stress, ceramide, and autophagy", J Lipid Res, 52, pp.1636~1651 (2011)
  112. Schaeffer L, "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids", Hum Mol Genet, 15, pp.1745~1756 (2006)
  113. Shearer GC, "Fish oil--how does it reduce plasma triglycerides?", Biochim Biophys Acta, 1821, pp.843~851 (2012)
  114. Scorletti E, "Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease", Annu Rev Nutr, 33, pp.231~248 (2013)
  115. Luukkonen PK, "Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars", Diabetes Care, 41, pp.1732~1739 (2018)
  116. Rosqvist F, "Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans", Diabetes, 63, pp.2356~2368 (2014)
  117. Bjermo H, "Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity : a randomized controlled trial", Am J Clin Nutr, 95, pp.1003~1012 (2012)
  118. Errazuriz I, "Randomized controlled trial of a MUFA or fiber-rich diet on hepatic fat in prediabetes", J Clin Endocrinol Metab, 102, pp.1765~1774 (2017)
  119. Bozzetto L, "Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients", Diabetes Care, 35, pp.1429~1435 (2012)
  120. Parker HM, "Omega-3 supplementation and non-alcoholic fatty liver disease : a systematic review and meta-analysis", J Hepatol, 56, pp.944~951 (2012)
  121. Lu W, "Effects of omega-3fatty acid in nonalcoholic fatty liver disease : a meta-analysis", Gastroenterol Res Pract, 2016, pp.1459790~ (2016)
  122. Argo CK, "Effects of n-3 fish oil on metabolic and histological parameters in NASH : a double-blind, randomized, placebo-controlled trial", J Hepatol, 62, pp.190~197 (2015)
  123. Razavi Zade M, "The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease : a randomized clinical trial", Liver Int, 36, pp.563~571 (2016)
  124. Kani AH, "Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease : a parallel randomized trial", Nutrition, 30, pp.814~821 (2014)
  125. Abenavoli L, "Diet and non-alcoholic fatty liver disease : the mediterranean way", Int J Environ Res Public Health, 16, pp.3011~ (2019)
  126. Ryan MC, "The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease", J Hepatol, 59, pp.138~143 (2013)
  127. Fraser A, "A modified mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients : results of a quasi-randomised controlled trial", Diabetologia, 51, pp.1616~1622 (2008)
  128. Kennedy OJ, "Systematic review with meta-analysis : coffee consumption and the risk of cirrhosis", Aliment Pharmacol Ther, 43, pp.562~574 (2016)
  129. Saab S, "Impact of coffee on liver diseases : a systematic review", Liver Int, 34, pp.495~504 (2014)
  130. Chen YP, "A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease", Clin Nutr, 38, pp.2552~2557 (2019)
  131. Wijarnpreecha K, "Coffee consumption and risk of nonalcoholic fatty liver disease : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 29, pp.e8~e12 (2017)
  132. van Dijk AE, "Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance", Diabetes Care, 32, pp.1023~1025 (2009)
  133. Herling AW, "Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system", Am J Physiol, 274, pp.G1087~G1093 (1998)
  134. Roerecke M, "Ethnicity matters : a systematic review and meta-analysis of the non-linear relationship between alcohol consumption and prevalence and incidence of hepatic steatosis", EBioMedicine, 8, pp.317~330 (2016)
  135. Sookoian S, "Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease : a metaanalysis of 43 175 individuals", Gut, 63, pp.530~532 (2014)
  136. Bellentani S, "Prevalence of and risk factors for hepatic steatosis in northern Italy", Ann Intern Med, 132, pp.112~117 (2000)
  137. Khoudari G, "Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort", World J Hepatol, 11, pp.710~718 (2019)
  138. Åberg F, "Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population", Hepatology, 67, pp.2141~2149 (2018)
  139. Hart CL, "Effect of body mass index and alcohol consumption on liver disease : analysis of data from two prospective cohort studies", BMJ, 340, pp.c1240~ (2010)
  140. Åberg F, "Binge drinking and the risk of liver events : a population-based cohort study", Liver Int, 37, pp.1373~1381 (2017)
  141. Ruhl CE, "Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population", Clin Gastroenterol Hepatol, 3, pp.1260~1268 (2005)
  142. Ekstedt M, "Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease", Scand J Gastroenterol, 44, pp.366~374 (2009)
  143. Åberg F, "Risks of light and moderate alcohol use in fatty liver disease : follow-up of population cohorts", Hepatology, 71, pp.835~848 (2020)
  144. Ajmera V, "Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis", Clin Gastroenterol Hepatol, 16, pp.1511~1520. e5 (2018)
  145. Hajifathalian K, "Effect of alcohol consumption on survival in nonalcoholic fatty liver disease : a national prospective cohort study", Hepatology, 70, pp.511~521 (2019)
  146. Dunn W, "Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease(NAFLD)", J Hepatol, 57, pp.384~391 (2012)
  147. Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
  148. Zeraatkar D, "Red and processed meat consumption and risk for allcause mortality and cardiometabolic outcomes : a systematic review and meta-analysis of cohort studies", Ann Intern Med, 171, pp.703~710 (2019)
  149. Han MA, "Reduction of red and processed meat intake and cancer mortality and incidence : a systematic review and meta-analysis of cohort studies", Ann Intern Med, 171, pp.711~720 (2019)
  150. Zeraatkar D, "Effect of lower versus higher red meat intake on cardiometabolic and cancer outcomes : a systematic review of randomized trials", Ann Intern Med, 171, pp.721~731 (2019)
  151. Vernooij RWM, "Patterns of red and processed meat consumption and risk for cardiometabolic and cancer outcomes : a systematic review and meta-analysis of cohort studies", Ann Intern Med, 171, pp.732~741 (2019)
  152. Carroll AE, "Meat consumption and health : food for thought", Ann Intern Med, 171, pp.767~768 (2019)
  153. Ioannidis JPA, "The challenge of reforming nutritional epidemiologic research", JAMA, 320, pp.969~970 (2018)
  154. Johnston BC, "Unprocessed red meat and processed meat consumption : dietary guideline recommendations from the nutritional recommendations(NutriRECS)consortium", Ann Intern Med, 171, pp.756~764 (2019)
  155. Harrison SA, "Orlistat for overweight subjects with nonalcoholic steatohepatitis : a randomized, prospective trial", Hepatology, 49, pp.80~86 (2009)
  156. Lin WY, "Efficacy and safety of verylow-calorie diet in Taiwanese : a multicenter randomized, controlled trial", Nutrition, 25, pp.1129~1136 (2009)

관련 논문AI추천

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver diseaseChristian Datz, Georg Semmler, Michael Trauner대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activityDonghee Kim, Min-Sun Kwak대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제1호The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver diseaseChristopher D. Byrne, Erica Jennison대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제1호Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver diseaseAijaz Ahmed, Donghee Kim, Peter Konyn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Non-alcoholic fatty liver disease: Definition and subtypes김문영, 백순구, Seul Ki Han대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Comparison between obese and non-obese nonalcoholic fatty liver diseaseWah-Kheong Chan대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호

이 간행물의 다른 논문 (39건)

Liver graft from donation after circulatory death donor: Real practice to improve graft viabilityKoji Hashimotopp. 401-410Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stopHyung Joon Yim, Jeong-Hoon Lee, Jun Yong Park, Eileen L. Yoon, Sae Hwan Lee, Hyun Woong Lee, Jung Hyun Kwon, Dong Hyun Sinn, Hana Park, Ji Hoon Kimpp. 411-429Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver diseaseKyung-Soo Kim, Byung-Wan Leepp. 430-443Managing liver cirrhotic complications: Overview of esophageal and gastric varicesCosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Ganipp. 444-460Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologySilvia Sookoian, Carlos J. Pirolapp. 461-475
원문 보기